most citedA general two-stage progressive model of cancer natural history to project downstaging due to multi-cancer screening tests

2 citations · 2 across the 2 of their papers we have counts for

collaborators
Showing econ.EMShow all

1 paper · 1 filter

econ.EM2023

The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design

Samantha E. Clark, Ruth Etzioni, Jerry Radich +2

Objective To assess the price elasticity of branded imatinib in chronic myeloid leukemia (CML) patients on Medicare Part D to determine if high out-of-pocket payments (OOP) are dri…